The Indiana University School of Medicine, Industry Collaboration Portal (ICP) was launched in 2014 with a vision to “create an ecosystem for collaborative research and entrepreneurship to ultimately improve human health”. The mission of ICP is to catalyze academic-industry partnerships, entrepreneurship, and training and education by leveraging synergistic expertise, capabilities, and innovations from IUSM and private industries.
Melanoma tumors switch to an alternative energy system when they develop resistance to chemotherapy, making that alternative system an attractive target for new treatments, according to researchers at Indiana University School of Medicine. These findings highlight the potential of this enzyme as a novel target for a new anti-melanoma therapy, Dr. Naidu said. "If we can develop a drug that can effectively inhibit this enzyme, we could extend the life of melanoma patients from months to years," he said.
The technology was developed by Mervin C. Yoder, M.D., the Richard and Pauline Klinger Professor of Pediatrics and professor of biochemistry and molecular biology at the Indiana University School of Medicine. He said a condition called peripheral arterial disease, caused by damaged blood vessels, diminishes blood flow to a person's lower extremities, with potentially serious consequences.
An Indiana University School of Medicine proposal to develop a comprehensive precision medicine initiative is one of five finalists selected to submit full proposals for funding through theIndiana University Grand Challenges Program, the most ambitious research program in the university's history. The program, launched in September, will invest up to $300 million over five years to address some of the most urgent challenges facing Indiana and the world.